<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645668</url>
  </required_header>
  <id_info>
    <org_study_id>XH-18-003</org_study_id>
    <nct_id>NCT03645668</nct_id>
  </id_info>
  <brief_title>Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients</brief_title>
  <official_title>Efficacy and Pharmacokinetics of Meropenem in Different Administration for Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experimental and control group were used different administration of Meropenem through
      monitoring the Meropenem plasma concentration and clinical data
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized controlled trial, which the subjects were severe
      sepstic patients for selecting Meropenem as antimicrobial drugs. The experimental and control
      group were used different administration of Meropenem through monitoring the Meropenem plasma
      concentration and clinical data, eventually demonstrate the effecacy and safety of Meropenem
      in patients with severe infection and optimize the best clinical practice for antimicrobial
      agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">December 14, 2019</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T&gt;MIC</measure>
    <time_frame>Day 1</time_frame>
    <description>Time above MIC% per administration interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>APACHE II score</measure>
    <time_frame>Day 0,Day 4,Day 8</time_frame>
    <description>Change of Acute physiology and chronic health evaluation score (APACHE II score) during period of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA</measure>
    <time_frame>Day 0,Day 4,Day 8</time_frame>
    <description>Change of Sepsis-related Organ Failure Assessment score (sofa) during period of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Mortality within 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>highest temperature</measure>
    <time_frame>Day 0,Day 4,Day 8</time_frame>
    <description>Variation of the highest temperature</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem Injection</intervention_name>
    <description>Different administration types between two groups</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>meropenem,MEPEM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Inpatients, whose informed consent has been obtained;

          2. Clinical diagnosis of Sepsis

        Exclusion Criteria:

          1. Pregnancy or lactation;

          2. Treated with other carbapenems;

          3. Cannot be evaluated for efficacy and safety result from lack of clinical and
             laboratory parameter for Infection assessment;

          4. Allergy to meropenem or other β-lactams, or the history of allergy;

          5. Resistant to meropenem according to the antimicrobial susceptibility test;

          6. Epilepsy or history of epilepsy;

          7. History of seizures;

          8. Combined medicine with sodium valproate;

          9. Combined medicine with anti-MRSA, anti-fungal drugs;

         10. with severe liver or renal dysfunction;

         11. Terminal cancer;

         12. Septic shock;

         13. APACH II ≥20;

         14. Inappropriate to participate in the trial evaluated by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aihua FEI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Xinhua Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis，meropenem，2 steps administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

